Regenxbio Inc (NASDAQ:RGNX) insider Kenneth T. Mills sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $68.25, for a total value of $1,365,000.00. Following the transaction, the insider now owns 322,500 shares in the company, valued at $22,010,625. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Regenxbio stock traded up $4.12 on Wednesday, hitting $73.80. 376,141 shares of the company were exchanged, compared to its average volume of 539,412. The stock has a market cap of $2.28 billion, a P/E ratio of -30.12, a P/E/G ratio of 14.16 and a beta of -0.49. Regenxbio Inc has a 1-year low of $23.25 and a 1-year high of $85.10.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported $0.15 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.90 by ($1.75). Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. The company had revenue of $40.03 million for the quarter, compared to analyst estimates of $100.00 million. As a group, research analysts forecast that Regenxbio Inc will post 1.64 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on the company. Chardan Capital boosted their target price on Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, July 10th. Morgan Stanley boosted their target price on Regenxbio from $37.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, July 13th. Bank of America cut Regenxbio from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $64.00 to $80.00 in a report on Monday, July 23rd. Raymond James boosted their target price on Regenxbio from $76.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, September 7th. Finally, TheStreet upgraded Regenxbio from a “d+” rating to a “c” rating in a report on Monday, September 17th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $83.50.
ILLEGAL ACTIVITY WARNING: “Kenneth T. Mills Sells 20,000 Shares of Regenxbio Inc (RGNX) Stock” was first reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/11/07/kenneth-t-mills-sells-20000-shares-of-regenxbio-inc-rgnx-stock.html.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.